Literature DB >> 35188645

Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.

Emma Arnesdotter1, Eva Gijbels1, Bruna Dos Santos Rodrigues1, Vânia Vilas-Boas1, Mathieu Vinken2.   

Abstract

Adverse outcome pathways (AOPs) are tools to capture and visualize mechanisms driving toxicological effects. They share a common structure consisting of a molecular initiating event, a series of key events connected by key event relationships and an adverse outcome. Development and evaluation of AOPs ideally comply with guidelines issued by the Organization for Economic Cooperation and Development. AOPs have been introduced for major types of hepatotoxicity, which is not a surprise, as the liver is a frequent target for systemic adversity. Various applications for AOPs have been proposed in the areas of toxicology and chemical risk assessment, in particular in relation to the establishment of quantitative structure-activity relationships, the elaboration of prioritization strategies, and the development of novel in vitro toxicity screening tests and testing strategies.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  AOP; Cancer; Cholestasis; Fibrosis; Liver toxicity; Steatosis

Mesh:

Year:  2022        PMID: 35188645     DOI: 10.1007/978-1-0716-1960-5_20

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  40 in total

Review 1.  Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment.

Authors:  Gerald T Ankley; Richard S Bennett; Russell J Erickson; Dale J Hoff; Michael W Hornung; Rodney D Johnson; David R Mount; John W Nichols; Christine L Russom; Patricia K Schmieder; Jose A Serrrano; Joseph E Tietge; Daniel L Villeneuve
Journal:  Environ Toxicol Chem       Date:  2010-03       Impact factor: 3.742

Review 2.  Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making.

Authors:  Stephen W Edwards; Yu-Mei Tan; Daniel L Villeneuve; M E Meek; Charlene A McQueen
Journal:  J Pharmacol Exp Ther       Date:  2015-11-04       Impact factor: 4.030

Review 3.  Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data.

Authors:  Jennifer Seed; Edward W Carney; Richard A Corley; Kevin M Crofton; John M DeSesso; Paul M D Foster; Robert Kavlock; Gary Kimmel; James Klaunig; M E Meek; R Julian Preston; William Slikker; Sonia Tabacova; Gary M Williams; Jeanette Wiltse; R Thomas Zoeller; Penelope Fenner-Crisp; Dorothy E Patton
Journal:  Crit Rev Toxicol       Date:  2005 Oct-Nov       Impact factor: 5.635

4.  Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.

Authors:  Richard A Becker; Gerald T Ankley; Stephen W Edwards; Sean W Kennedy; Igor Linkov; Bette Meek; Magdalini Sachana; Helmut Segner; Bart Van Der Burg; Daniel L Villeneuve; Haruna Watanabe; Tara S Barton-Maclaren
Journal:  Regul Toxicol Pharmacol       Date:  2015-04-08       Impact factor: 3.271

5.  Adverse outcome pathway (AOP) development I: strategies and principles.

Authors:  Daniel L Villeneuve; Doug Crump; Natàlia Garcia-Reyero; Markus Hecker; Thomas H Hutchinson; Carlie A LaLone; Brigitte Landesmann; Teresa Lettieri; Sharon Munn; Malgorzata Nepelska; Mary Ann Ottinger; Lucia Vergauwen; Maurice Whelan
Journal:  Toxicol Sci       Date:  2014-12       Impact factor: 4.849

Review 6.  Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop.

Authors:  M S Bogdanffy; G Daston; E M Faustman; C A Kimmel; G L Kimmel; J Seed; V Vu
Journal:  Toxicol Sci       Date:  2001-05       Impact factor: 4.849

Review 7.  A framework for human relevance analysis of information on carcinogenic modes of action.

Authors:  M E Bette Meek; John R Bucher; Samuel M Cohen; Vicki Dellarco; Richard N Hill; Lois D Lehman-McKeeman; David G Longfellow; Timothy Pastoor; Jennifer Seed; Dorothy E Patton
Journal:  Crit Rev Toxicol       Date:  2003       Impact factor: 5.635

Review 8.  Adverse outcome pathways: a concise introduction for toxicologists.

Authors:  Mathieu Vinken; Dries Knapen; Lucia Vergauwen; Jan G Hengstler; Michelle Angrish; Maurice Whelan
Journal:  Arch Toxicol       Date:  2017-06-28       Impact factor: 5.153

9.  Adverse Outcome Pathways can drive non-animal approaches for safety assessment.

Authors:  Natalie Burden; Fiona Sewell; Melvin E Andersen; Alan Boobis; J Kevin Chipman; Mark T D Cronin; Thomas H Hutchinson; Ian Kimber; Maurice Whelan
Journal:  J Appl Toxicol       Date:  2015-05-05       Impact factor: 3.446

10.  The Key Events Dose-Response Framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds.

Authors:  Elizabeth Julien; Alan R Boobis; Stephen S Olin
Journal:  Crit Rev Food Sci Nutr       Date:  2009-09       Impact factor: 11.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.